NCT07593157Not yet recruiting
Invasive Evaluation and Phenotype-Guided Treatment of ANOCA in Women
Invasive Functional and Morphological Coronary Assessment Followed by Phenotype-Guided Multidisciplinary Treatment in Women With Angina and Non-Obstructive Coronary Arteries: A Prospective Single-Center Interventional Study
Source: ClinicalTrials.gov · Last updated 18 May 2026
Brief summary (registry, in English)
This prospective single-center interventional study will include women with angina and non-obstructive coronary arteries. Participants will undergo a standardized invasive coronary assessment combining coronary physiology, acetylcholine provocation testing, and optical coherence tomography. The diagnostic protocol will identify functional and morphological mechanisms of angina, including microvascular dysfunction, epicardial vasospasm, microvascular spasm, endothelial dysfunction, functional epicardial disease, combined mechanisms, or normal coronary physiology. Based on the identified phenotype, participants will receive individualized multidisciplinary treatment, including targeted pharmacological therapy, adapted cardiovascular rehabilitation, and psycho-emotional support when indicated. Clinical follow-up will be performed at 1, 6, and 12 months to assess angina symptoms, quality of life, functional capacity, adherence to treatment, and cardiovascular events.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 10 May 2026
- Start date
- 15 May 2026
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Hospital de Clínicas Dr. Manuel Quintela
- Diseases
- Coronary artery disease
- NCT number
- NCT07593157
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 15 May 2026 to the primary completion date, 30 Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant structural heart disease.
- Clinically relevant contraindication to adenosine or acetylcholine, including severe asthma, untreated high-grade atrioventricular block, or known hypersensitivity.
- Active oncological disease or life expectancy less than 12 months.
Lab values
- Severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction \<40%.
Other
- Inability to complete the diagnostic or therapeutic study protocol.
- Participation in another clinical study that could interfere with the present protocol.
Who the study is looking for
- Female participants aged 35 to 75 years.
- Symptoms compatible with stable angina or suspected myocardial ischemia.
- Non-obstructive coronary arteries, defined as absence of angiographic stenosis greater than or equal to 50%.
- Ability to undergo invasive coronary assessment and clinical follow-up.
- Written informed consent.
Age in the registry: 35 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital de Clinicas Dr Manuel Quintela Coordinator of this site? Confirm its status | Montevideo | Uruguay | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.